Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer (Q24299807)

Steroid 5 alpha-reductase 1

GOA release 2020-03-11

1 reference

3-oxo-5-alpha-steroid 4-dehydrogenase activity

GOA release 2020-03-11

1 reference

GOA release 2020-03-11

1 reference

1 reference

2

Kenji Tamura

0 references

Hidewaki Nakagawa

7

object named as

Hidewaki Nakagawa

0 references

author name string

Motohide Uemura

1

0 references

Suyoun Chung

3

0 references

Seijiro Honma

4

0 references

Akihiko Okuyama

5

0 references

Yusuke Nakamura

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

6

0 references

language of work or name

English

0 references

publication date

January 2008

0 references

published in

Cancer Science

0 references

volume

99

0 references

page(s)

81-6

0 references

issue

1

0 references

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2007.00656.X

The development of androgen-independent prostate cancer

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Trends and patterns of prostate cancer: what do they suggest?

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Site-directed mutagenesis studies of the NADPH-binding domain of rat steroid 5alpha-reductase (isozyme-1) I: analysis of aromatic and hydroxylated amino acid residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Neurosteroid biosynthesis in the human brain and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

Prostate cancer epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Natural Mutagenesis Study of the Human Steroid 5.alpha.-Reductase 2 Isoenzyme

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00656.X

7 January 2021